Breviscapine is extracted from Erigeron breviscapus, the main component of which is scutellarin. Breviscapine has a good pharmacological activity in the treatment of cardiovascular and cerebrovascular diseases. The oral bioavailability of ordinary tablets and granules is very low; at the same time, the half-life of ordinary injection and injection powder is short, eliminating quickly in the body. Therefore, the new preparations for breviscapine such as liposomal injections, microcapsules, sublingual tablets, orally disintegrating tablets, self-emulsifying soft capsules, and other quick-release preparations are in the stage of development.
KeywordsBreviscapine Scutellarin Cardiovascular diseases Cerebrovascular diseases
- 1.Yunnan Institute of Materia Medica. Study on the chemical components of Erigeron breviscapus. Chin Herb Med Commun. 1976;11:11–4.Google Scholar
- 2.Yang WY, Zhang Y. The folk application status of Erigeron breviscapus. Chin Med Newsp. 2005;5(31):A07.Google Scholar
- 3.Cui JM, Wu S. Advances in research on breviscapine. Nat Prod Res Dev. 2003;15(3):255–8.Google Scholar
- 4.Yang LM, Gu J, Lin MJ, et al. Advances in research on breviscapine. Tianjin Pharm. 2010;22(1):56–60.Google Scholar
- 5.Zhang XD, Liu J, Zhang WB, et al. Research advance on cardiovascular pharmacological and clinical application of breviscapine. China Pharm. 2007;16(21):3–5.Google Scholar
- 8.Wei N. Advances of breviscapine in clinical applications and its side-effects. China Pharm. 2011;4(2):144–6.Google Scholar